Navigation Links
Fero Industries, Inc. Issues Corporate Update

CALGARY, Canada, Dec. 6, 2012 /PRNewswire/ -- Fero Industries, Inc. (OTC: FROI), the exclusive producer, marketer & distributor of Sucanon®, an oral type-2 Diabetes treatment, today issued a shareholder update, recapping the major events of 2012, and announced additional changes expected in 2013.

"I would first like to take this opportunity to thank our loyal shareholders for their support and belief in our company through a year that was full of changes. Our shareholders' loyalty has been a source of pride for Fero, and it makes us that much more committed to protecting their investment," stated Luis Lopez, CEO of Fero Industries.

Earlier this year, The Company announced executive management and Board Member changes, which were approved via proxy by the majority of FROI shareholders. "These actions were taken to protect the shareholders, and I feel that they deserve for Fero's executive team to have the vision and necessary expertise to move the company forward," Mr. Lopez went on to say.

Another important event for Fero in 2012 was the majority shareholder approval of a reverse stock split, which would nullify a 1 for 5 forward split approved by the previous management in 2009 that was unnecessary. While Company management fully agrees that the reversal of the forward split can and should be done, timing can be critical in these situations, and moving forward with the reverse would not be productive at this time.   

"I would also like to take the time to address our previously announced agreement with Premium Pharma in the Middle East," said Mr. Lopez. "As you may or may not know, the US and many of its allies around the world are currently in an embargo with Iran. Premium Pharma is located in Iran, and therefore subject to the embargo. However, since they are a Health-Care distribution company, they are not on any restricted lists. In fact, they distribute multiple products from US-based companies. We were required to fill out and file an official questionnaire concerning the agreement with Premium Pharma, and due to changes in the Treasury, have been asked to re-submit the paperwork. We are currently in the process of fulfilling this request, and have good reason to believe that the necessary approval is imminent."

Moving forward, there will be additional corporate modifications such as an address and phone number with a Colorado designation, since Fero has moved its domicile from Canada to Colorado. The Company will also be filing for a corporate name change, to PharmaRoth Labs, in early 2013. Once the name change is approved and effective, the Company will begin the process of filing for a ticker symbol change to better reflect its core business.

The Company has not been current with filing its financials with the SEC, and has been exploring alternate disclosure methods so as to give our shareholders a strong picture of the company. "Becoming as transparent as we possibly can is a top priority for us, and I expect to have a viable solution in the very near future," Mr. Lopez stated.

"I am also aggressively working to greatly expand our relationships with pharmaceutical companies around the world. I believe that 2013 will be a breakthrough year for increased exposure of Sucanon into new markets. Our product is the only Type II Diabetes drug with no side effects and high efficacy. This incredible combination of attributes is the key strength of our company."

"In conclusion, I would like to say that we have been working very hard to increase our market penetration in turbulent corporate times. I believe we are now well positioned to move forward as a company in a more aggressive way. I look forward to 2013 and beyond!"

About Sucanon®

Sucanon® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers".  Pre-clinical and clinical studies show that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin.  Sucanon® has been approved for prescription sale in China and Peru.  Sucanon® is also approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.

For further information regarding Sucanon®, please visit the Fero Industries Inc. website at

About Fero Industries Inc.

Fero Industries, Inc. (OTC: FROI) is focused on diabetes prevention and treatments.  The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes.  Sucanon® is a member of a class of diabetic medications called insulin sensitizers.  Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin.  Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.  Fero's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

For investor relations contact:

Michael Irving 
Paramount Advisors, LLC
(407) 878-5462

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions.  Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Fero Industries, Inc. (the Company) to be materially different from those expressed or implied by such forward-looking statements.

The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at under "Search for Company Filings".

SOURCE Fero Industries, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sun Pharmaceutical Industries, Inc. Issues Nationwide Voluntary Recall of One Lot of Nimodipine Capsules due to Crystallization of the Fill Material
2. Lower Operating Expense Augments Digital X-rays Uptake Across Industries, Finds Frost & Sullivan
3. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
4. CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
5. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
6. Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Companys Phase III FDA Sickle Cell Treatment Trials
7. Zi Xiu Tang Success, LLC Issues Voluntary Nationwide Recall of Classic Zi Xiu Tang Bee Pollen Capsules and Ultimate Formula Capsules due to Undeclared Sibutramine
8. CORRECTION: Star Scientific Issues Statement Correcting the Underreporting of the "Flint" CRP Human Study Results
9. Qualitest Issues Voluntary, Nationwide Recall for One Lot of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
10. Health Outcome Liaisons Improve Decision Making for Pharmaceutical Industry Challenged by Reform and Compliance Issues
11. Joint Commission Issues Sentinel Event Alert on Opioid-Induced Respiratory Depression
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Lexicon Pharmaceuticals, Inc. ... top-line data from its TELECAST Phase 3 ... treating carcinoid syndrome in cancer patients with ... benefit observed in its pivotal TELESTAR study.  ... companion to TELESTAR primarily to provide additional ...
(Date:12/1/2015)... , Dec. 1, 2015  ImmunoCellular Therapeutics, ... Andrew Gengos , President and Chief ... on December 3, 2015. Mr. Gengos plans ... registrational program in patients with newly diagnosed ... TIME:    12:15p.m. ET/9:15a.m. PT LINK: ...
(Date:12/1/2015)... and UPPSALA, Sweden , December ... been selected by the International Breast Cancer Study Group (IBCSG, ... (BIG, Brussels ) to be part of ... palbociclib, a promising new cancer drug.  --> ... women with advanced breast cancer being treated with anti-hormonal therapy ...
Breaking Medicine Technology:
(Date:12/1/2015)... PA (PRWEB) , ... December 01, 2015 , ... ... imaging facilities, radiographic technicians must mark the film for accurate interpretation by the ... track of. Fortunately, an inventor from Sacramento, Calif., has found a way to ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... honors Christina Colon as a 2015-2016 inductee into its VIP Woman ... in pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, ...
Breaking Medicine News(10 mins):